Multivariate Markov models for the conditional probability of toxicity in phase II trials [0.03%]
多元马尔可夫模型在II期临床试验中用于计算毒性条件概率的方法研究
Laura L Fernandes,Susan Murray,Jeremy M G Taylor
Laura L Fernandes
In addition to getting a preliminary assessment of efficacy, phase II trials can also help to determine dose(s) that have an acceptable toxicity profile over repeated cycles as well as identify subgroups with particularly poor toxicity prof...
Bayesian semiparametric analysis of recurrent failure time data using copulas [0.03%]
基于Copula的复发事件数据的半参数贝叶斯分析方法研究
Renate Meyer,Jose S Romeo
Renate Meyer
The analysis of recurrent event data is of particular importance in medical statistics where patients suffering from chronic diseases often present with multiple recurring relapses or cancer patients experience several tumor recurrences. Wh...
Vera Djordjilović,Monica Chiogna,M Sofia Massa et al.
Vera Djordjilović et al.
Current demand for understanding the behavior of groups of related genes, combined with the greater availability of data, has led to an increased focus on statistical methods in gene set analysis. In this paper, we aim to perform a critical...
Analysis of interval-censored recurrent event processes subject to resolution [0.03%]
关于解决的区间截断型复发事件过程的分析
Hua Shen,Richard J Cook
Hua Shen
Interval-censored recurrent event data arise when the event of interest is not readily observed but the cumulative event count can be recorded at periodic assessment times. In some settings, chronic disease processes may resolve, and indivi...
Ines Wilms,Christophe Croux
Ines Wilms
Canonical correlation analysis (CCA) describes the associations between two sets of variables by maximizing the correlation between linear combinations of the variables in each dataset. However, in high-dimensional settings where the number...
Does it help that efficacy has been proven once we start discussing (added) benefit? [0.03%]
有效性一旦确立，再讨论其益处有意义吗？
Armin Koch,Yvonne Ziert
Armin Koch
Since the introduction of benefit assessment to support reimbursement decisions in Germany there seems to be the impression that totally distinct methodology and strategies for decision making would apply in the field of drug licensing and ...
Semiparametric transformation models for multiple continuous biomarkers in ROC analysis [0.03%]
半参数转化模型在受控于多个连续生物标志物的ROC分析中的应用
Eunhee Kim,Donglin Zeng,Xiao-Hua Zhou
Eunhee Kim
Recent technological advances continue to provide noninvasive and more accurate biomarkers for evaluating disease status. One standard tool for assessing the accuracy of diagnostic tests is the receiver operating characteristic (ROC) curve....
Zhanfeng Wang,Xiangyu Luo,Yuan-chin I Chang
Zhanfeng Wang
As medical research and technology advance, there are always new biomarkers found and predictive models proposed for improving the diagnostic performance of diseases. Therefore, in addition to the existing biomarkers and predictive models, ...
Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs [0.03%]
新药早期疗效评估中确定次要疗效、重大疗效和重要疗效的方法学研究
Guido Skipka,Beate Wieseler,Thomas Kaiser et al.
Guido Skipka et al.
At the beginning of 2011, the early benefit assessment of new drugs was introduced in Germany with the Act on the Reform of the Market for Medicinal Products (AMNOG). The Federal Joint Committee (G-BA) generally commissions the Institute fo...
Agglomerative joint clustering of metabolic data with spike at zero: A Bayesian perspective [0.03%]
基于Bayesian理论的代谢数据在零点爆破下的聚合联合聚类方法
Vahid Partovi Nia,Mostafa Ghannad-Rezaie
Vahid Partovi Nia
In many biological applications, for example high-dimensional metabolic data, the measurements consist of several continuous measurements of subjects or tissues over multiple attributes or metabolites. Measurement values are put in a matrix...